recent
advanc
technolog
last
decad
propel
microbiolog
laboratori
pivot
role
infect
prevent
control
rapid
adapt
molecular
technolog
field
clinic
microbiolog
greatli
influenc
infecti
diseas
manag
significantli
impact
infect
control
practic
review
discuss
recent
develop
molecular
techniqu
diagnosi
infecti
diseas
describ
basic
concept
molecular
assay
discuss
advantag
limit
character
current
avail
commerci
assay
respect
cost
interpret
requir
clinic
util
microbiolog
laboratori
alway
play
import
role
public
health
howev
recent
advanc
technolog
last
decad
propel
laboratori
pivot
role
infect
prevent
control
health
care
commun
set
rapid
adapt
molecular
technolog
field
clinic
microbiolog
greatli
influenc
infecti
diseas
manag
significantli
impact
infect
control
practic
molecular
assay
instanc
replac
need
tradit
test
method
viral
cultur
herpesvirus
enterovirus
concurr
advanc
autom
inform
technolog
made
possibl
critic
diagnost
inform
greatest
impact
decis
isol
treatment
care
effect
use
molecular
diagnost
technolog
enhanc
infect
control
practic
import
understand
scope
rapid
diagnost
test
appreci
need
judici
interpret
collabor
clinic
microbiologist
review
discuss
recent
develop
molecular
techniqu
diagnosi
infecti
diseas
begin
describ
basic
concept
molecular
assay
discuss
advantag
limit
conclud
character
current
avail
commerci
assay
respect
cost
interpret
requir
clinic
util
molecular
assay
current
use
base
detect
nucleic
acid
target
pathogen
one
follow
procedur
target
amplif
signal
amplif
nonamplif
method
mani
molecular
assay
use
clinic
laboratori
base
polymeras
chain
reaction
pcr
amplif
dna
rna
pathogen
organ
interest
pcr
perform
directli
patient
specimen
altern
organ
isol
purpos
pcr
amplifi
nucleic
acid
interest
detect
limit
basic
format
vitro
reaction
use
set
reagent
thermost
polymeras
enzym
synthes
million
copi
target
nucleic
acid
also
known
amplicon
process
thermal
cycl
wherebi
strand
dna
rna
duplic
multipl
time
repeat
cycl
illustr
pcr
method
avail
onlin
http
www
sumanasinccomwebcontentanimationscontentpcrhtml
primer
pair
forward
revers
specif
target
dna
sequenc
use
creat
ident
strand
vari
length
base
design
primer
requir
assay
repeat
thermal
cycl
chain
reaction
use
gener
exponenti
amount
dna
potenti
increas
sensit
sever
hundredfold
amplifi
rna
target
influenza
respiratori
syncyti
viru
rsv
human
immunodefici
viru
hiv
hepat
c
viru
hcv
reversetranscript
pcr
use
reversetranscript
pcr
includ
initi
step
convert
rna
target
complimentari
dna
cdna
subsequ
thermocycl
amplif
cdna
perform
pcr
nest
heminest
pcr
modif
made
increas
sensit
specif
target
amplif
nest
pcr
primer
pair
use
amplif
first
pair
amplifi
origin
target
second
pair
bind
sequenc
within
product
first
pair
amplifi
segment
shorter
origin
target
rational
select
specif
amplif
product
use
second
primer
pair
within
first
amplicon
therefor
increas
sensit
specif
assay
amplificationbas
assay
incorpor
detect
method
wherebi
product
amplif
record
sever
modif
basic
pcr
technolog
detect
amplifi
product
use
laboratori
perhap
use
realtim
pcr
assay
rtpcr
realtimepcr
revolution
direct
detect
pathogen
clinic
specimen
technolog
incorpor
use
fluoresc
dye
amplif
reaction
use
optic
monitor
fluoresc
emiss
end
cycl
inclus
softwar
examin
interpret
reaction
kinet
realtim
gener
amplif
plot
reaction
expedit
process
target
detect
significantli
fig
use
multipl
fluoresc
dye
rtpcr
multiplex
therefor
detect
sever
target
achiev
reaction
exampl
xpert
ctng
assay
cepheid
sunnyval
ca
use
specif
primer
chlamydia
trachomati
neisseria
gonorrhoea
therefor
facilit
detect
either
specimen
interpret
rtpcr
result
requir
understand
demonstr
figur
reaction
threshold
fluoresc
signal
akin
background
fluoresc
cycl
fluoresc
targetspecimen
cross
rise
threshold
fluoresc
known
cycl
threshold
ct
ct
use
criterion
result
interpret
cutoff
posit
neg
set
certain
ct
base
valid
result
assay
design
mani
rtpcr
chemistri
also
use
addit
melt
curv
specif
identif
amplifi
product
melt
curv
gener
increas
temperatur
slowli
measur
fluoresc
temperatur
increas
dna
strand
denatur
temperatur
specif
sequenc
dna
segment
melt
temperatur
lead
decreas
fluoresc
fig
temperatur
occur
provid
indic
size
amplicon
therefor
enabl
differenti
nonspecif
amplif
melt
curv
also
use
differenti
target
amplicon
design
differ
melt
temperatur
specif
detail
variou
method
individu
discuss
diseas
topic
gener
advantag
pcr
includ
abil
detect
even
low
number
pathogen
provid
increas
sensit
contrast
cultur
requir
hour
week
growth
fungi
mycobacterium
tuberculosi
mtb
pcr
provid
result
hour
import
note
howev
amplif
dna
depend
viabil
organ
although
could
advantag
situat
posit
pcr
result
interpret
caution
nonviabl
pathogen
may
contribut
diseas
pathogenesi
similarli
pcr
assay
may
suitabl
followup
treat
infect
test
cure
assay
also
often
unabl
differenti
asymptomat
carriag
infect
exampl
pcr
assay
haemophilu
influenza
throat
swab
would
limit
valu
h
influenza
often
commens
upper
respiratori
tract
previous
molecular
test
requir
multipl
step
use
complex
chemistri
suit
perform
special
molecular
laboratori
train
personnel
complex
natur
previou
version
molecular
assay
addit
disadvantag
possibl
extran
contamin
lead
falseposit
result
sever
advanc
technolog
includ
autom
nanotechnolog
simplifi
inher
complex
earlier
methodolog
fact
mani
recent
develop
assay
requir
littl
handson
time
incorpor
extract
amplif
detect
singl
modul
rtpcr
amplif
detect
perform
within
close
reaction
vessel
less
manipul
reagent
consequ
reduc
opportun
releas
amplifi
dna
environ
product
pcr
con
tain
system
less
prone
contamin
decreas
likelihood
falseposit
result
subsequ
run
moreov
amplif
detect
real
time
significantli
reduc
time
requir
assay
complet
simplic
compact
food
drug
administr
fda
approv
cartridgebas
instrument
acceler
implement
molecular
assay
clinic
laboratori
especi
featur
random
access
make
instrument
user
friendli
instrument
capabl
high
throughput
test
especi
benefici
highvolum
period
influenza
season
platform
design
close
system
mean
approv
regulatori
agenc
run
specif
set
assay
specifi
specimen
type
assay
often
design
moder
complex
typic
sampl
result
assay
minim
sampl
prepar
need
test
instrument
softwar
includ
provid
posit
neg
report
requir
limit
interpret
laboratori
personnel
advent
new
type
assay
test
may
previous
refer
larger
laboratori
reclaim
smaller
laboratori
minim
technic
expertis
although
pcr
highli
sensit
effici
method
amplifi
target
region
dna
rna
repeat
thermal
cycl
requir
time
energi
amplif
isotherm
amplif
method
prefer
pointofcar
test
especi
resourc
limit
area
energi
effici
two
common
isotherm
amplif
method
common
use
nucleic
acid
sequencebas
amplif
nasba
transcriptionmedi
amplif
tma
method
rna
amplif
occur
base
retrovir
replic
model
rna
target
revers
transcrib
cdna
use
revers
transcriptas
enzym
primer
contain
promot
region
rna
strand
rnacdna
hybrid
degrad
either
endogen
rnaas
h
activ
tma
use
ad
rnaas
h
enzym
nasba
cdna
strand
get
amplifi
dna
polymeras
activ
revers
transcriptas
use
second
primer
produc
doublestrand
dna
contain
promot
sequenc
lead
synthesi
copi
rna
target
sequenc
continu
cycl
amplif
subsequ
detect
amplicon
achiev
hybrid
assay
use
chemiluminesc
fluoresc
probe
tma
nasba
primerdriven
synthesi
target
nucleic
acid
therefor
primer
design
import
assay
develop
howev
singlestrand
rna
product
unlik
convent
pcr
temperaturedriven
denatur
primer
anneal
requir
make
reaction
isotherm
theoret
approxim
minut
copi
gener
therefor
enabl
sensit
detect
rna
target
shorter
time
use
multienzym
complex
system
inher
difficulti
method
amplifi
doublestrand
dna
requir
denatur
deterr
widespread
use
addit
end
point
amplif
chemiluminesc
probe
use
detect
amplifi
product
hybrid
subsequ
protect
hybrid
product
add
level
complex
assay
isotherm
reaction
includ
other
strand
displac
amplif
loopmedi
isotherm
amplif
lamp
also
use
commerci
assay
particularli
favor
resourcelimit
area
thermocycl
equip
may
easili
avail
extens
use
technolog
resourcelimit
set
lamp
wide
evalu
diagnosi
malaria
tuberculosi
tb
sensit
specif
malaria
detect
report
high
use
lamp
technolog
recent
studi
sensit
specif
lamp
technolog
found
compar
genexpert
tbrif
assay
cepheid
sunnyval
ca
price
assay
rang
depend
whether
develop
local
purchas
commerci
lamp
assay
attract
pointofcar
diagnost
field
major
hindranc
use
isotherm
amplif
techniqu
complex
primer
design
need
sensit
detect
strategi
disadvantag
nucleic
acid
amplif
test
naat
includ
cost
initi
instrument
setup
commerci
assay
system
compar
convent
cultur
method
anoth
potenti
concern
interpret
assay
although
actual
result
easi
record
clinic
interpret
mani
assay
challeng
signal
amplif
technolog
design
avoid
potenti
contamin
reaction
target
nucleic
acid
instead
amplif
dna
rna
use
enzym
assay
amplifi
signal
gener
probe
hybrid
target
dna
amplif
target
involv
likelihood
extran
contamin
reduc
reason
signal
proport
amount
target
make
use
quantit
assay
although
target
amplif
assay
inher
sensit
signal
amplif
assay
often
prefer
especi
measur
viral
rna
blood
revers
transcript
convers
cdna
requir
branch
dna
assay
hybrid
captur
assay
cleavas
invad
assay
exampl
signal
amplificationbas
assay
use
quantit
assay
hiv
detect
hpv
n
gonorrhea
c
trachomati
use
nucleic
acid
probe
short
fragment
dna
rna
peptid
nucleic
acid
bind
target
interest
use
detect
pathogen
without
need
amplif
probe
usual
tag
chemiluminesc
fluoresc
enzymebas
report
molecul
facilit
detect
essenti
hybrid
reaction
complementari
strand
probe
hybrid
target
nucleic
acid
specimen
subsequ
detect
attach
report
molecul
method
lack
sensit
amplif
techniqu
larg
amount
target
present
posit
blood
cultur
bottl
techniqu
facilit
identif
pathogen
short
period
time
common
platform
use
microarraybas
verigen
blood
cultur
test
nanospher
northbrook
il
provid
identif
bacteria
also
detect
resist
mechan
directli
posit
blood
cultur
bottl
situ
hybridizationbas
peptid
nucleic
acid
fish
assay
advandx
woburn
whole
genom
microorgan
becom
avail
inform
use
develop
new
technolog
use
clinic
applic
microarray
exampl
effort
involv
immobil
multitud
dna
fragment
glass
surfac
bead
array
use
conjunct
hybrid
fluoresc
label
multiplex
detect
pathogen
analysi
genom
array
situ
solid
phase
liquid
bead
base
pcrbase
oligonucleotidebas
array
potenti
multiplex
technolog
immens
use
simultan
identif
genotyp
microb
discuss
regard
advanc
clinic
microbiolog
would
incomplet
without
mention
matrixassist
laser
desorptionion
timeofflight
malditof
technolog
advanc
made
much
impact
identif
microb
almost
centuri
pathogen
identif
posit
cultur
base
morpholog
metabol
profil
use
biochem
reaction
malditof
use
laser
puls
ioniz
analyt
molecul
desorb
gaseou
phase
allow
pass
electr
field
acceler
separ
base
mass
charg
mz
pattern
gener
match
databas
identif
malditof
reduc
turnaround
time
identif
bacteria
yeast
mycobacteria
hour
minut
also
use
identifi
pathogen
directli
blood
cultur
preliminari
studi
show
antimicrobi
suscept
predict
use
techniqu
advent
dnabas
identif
method
especi
sequenc
ribosom
rna
gene
made
rapid
precis
identif
pathogen
possibl
tradit
sanger
sequenc
nextgener
sequenc
ng
technolog
use
identifi
pathogen
directli
fresh
formalinfix
specimen
technolog
also
use
phylogenet
analys
outbreak
strain
reconstruct
transmiss
implement
infect
control
measur
howev
technolog
complex
expens
routin
use
clinic
laboratori
current
impract
concept
mind
remaind
articl
organ
accord
specif
diseas
differ
assay
use
detect
diagnosi
acidfast
smear
cultur
continu
mainstay
diagnos
tb
laboratori
comparison
tradit
cultur
take
week
molecular
assay
detect
mtb
directli
sputum
specimen
type
hour
provid
strong
incent
use
diagnosi
tb
although
intern
public
health
agenc
stress
use
naat
supplement
rather
replac
cultur
molecular
test
advoc
mean
earli
diagnosi
facilit
time
implement
infect
control
strategi
airborn
isol
earli
institut
appropri
therapi
dramat
influenc
patient
outcom
earli
notif
public
health
author
lead
intervent
home
workplac
school
social
profession
set
discontinu
airborn
isol
precaut
reduct
number
contact
investig
patient
neg
naat
per
center
diseas
control
prevent
cdc
guidelin
commerci
avail
assay
use
direct
detect
mtb
respiratori
specimen
includ
sputum
bronchoalveolar
lavag
includ
follow
xpert
tbrif
assay
cepheid
holog
amplifi
mycobacterium
tuberculosi
direct
test
holog
genprob
inc
san
diego
ca
xpert
tbrif
heminest
rtpcr
use
molecular
beacon
chemistri
detect
mtb
rifampin
resist
amplif
rpob
gene
clinic
specimen
holog
amplifi
mycobacterium
tuberculosi
direct
test
use
isotherm
transcriptionmedi
amplif
techniqu
assay
detect
rifampin
resist
accept
specimen
assay
includ
sputum
bronchial
lavagesaspir
tracheal
aspir
limit
detect
coloni
form
unit
use
dna
extract
pure
cultur
turnaround
time
assay
hour
result
assay
obtain
hour
day
wherea
tradit
cultur
suscept
method
result
could
take
week
longer
allow
improv
patient
outcom
appropri
institut
therapi
lead
substanti
cost
save
base
institut
isol
procedur
mani
resourcelimit
area
rapid
diagnosi
tb
achiev
microscopi
rather
inexpens
lack
sensit
compar
cultur
microscopi
detect
pulmonari
tb
case
microscopi
also
low
posit
predict
valu
tb
area
nontb
mycobacteria
isol
recent
metaanalysi
xpert
tbrif
assay
pool
sensit
specif
respect
initi
test
replac
smear
microscopi
multipl
studi
xpert
tbrif
shown
outperform
smear
microscopi
establish
diagnosi
tb
smearneg
case
sensit
predict
rifampicin
resist
high
accuraci
assay
limit
detect
mtb
sputum
coloni
form
unitsml
assay
perform
cepheid
genexpert
within
cartridg
reagent
specimen
contain
within
system
extran
contamin
biosafeti
concern
remain
requir
minim
handson
time
minut
assay
especi
use
highpreval
lowresourc
area
treatment
initi
earli
rapid
diagnosi
often
site
collect
fact
technolog
endors
world
health
organ
frontlin
test
tb
popul
high
incid
suspect
multidrugresist
tb
hivassoci
tb
perform
mycobacteri
cultur
labor
intens
may
feasibl
small
laboratori
minim
experi
procedur
patient
popul
low
incid
tb
eas
simplic
assay
allow
remot
laboratori
less
special
technologist
perform
test
mtb
naat
technolog
significantli
improv
timeli
accuraci
test
result
guid
infect
control
decis
manag
patient
tb
infect
xpert
tbrif
assay
cepheid
shown
significantli
reduc
airborn
infect
isol
time
individu
hospit
without
activ
tb
although
molecular
test
improv
diagnosi
mtb
cultur
still
import
detect
nontb
mycobacteria
perform
phenotyp
suscept
test
mtb
molecular
assay
consid
test
choic
cdc
diagnosi
sexual
transmit
infect
sti
adult
chlamydi
infect
asymptomat
patient
often
return
followup
initi
visit
rapid
diagnost
test
initi
treatment
essenti
control
sti
addit
naat
found
sensit
diagnosi
chlamydi
infect
tradit
cultur
method
sever
fdaapprov
fdaclear
test
avail
screen
specimen
c
trachomatisn
gonorrhoea
ctng
current
avail
assay
simultan
amplifi
ctng
use
rtpcr
tma
strand
displac
amplif
assay
depend
assay
either
ribosom
rna
gene
cryptic
plasmid
c
trachomati
target
tabl
target
specif
c
trachomati
crossreact
human
bacteria
n
gonorrhoea
segment
ribosom
rna
pilin
opa
protein
target
mostli
specif
howev
assay
primer
n
gonorrhoea
may
cross
react
human
commens
speci
neisseria
becom
especi
import
use
naat
specimen
pharyng
rectal
swab
refer
standard
diagnosi
less
sensit
cultur
method
particularli
difficult
demonstr
perform
characterist
molecular
assay
sti
tabl
therefor
lack
consensu
regard
optim
method
valid
naat
sensit
older
assay
like
overestim
poor
perform
standard
test
time
sensit
specif
bias
area
low
diseas
preval
better
valid
method
becom
avail
public
health
author
recommend
naat
diagnosi
ctng
adult
men
women
signific
concern
molecular
assay
diagnos
sti
microbi
isol
avail
test
antimicrobi
suscept
emerg
multidrugresist
n
gonorrhoea
extens
drugresist
n
gonorrhoea
rise
concern
may
becom
untreat
superbug
author
maintain
strengthen
culturebas
surveil
local
resist
pattern
increasingli
import
tool
detect
resist
n
gonorrhoea
strain
monitor
spread
accomplish
microbiolog
cultur
requir
perform
suscept
test
therefor
cdc
recommend
cultur
suscept
patient
suspect
treatment
failur
anoth
area
concern
use
naat
diagnosi
suspect
sexual
abus
minor
case
advis
check
local
regul
author
naat
accept
molecular
assay
often
method
avail
detect
viral
pathogen
use
commerci
avail
quantit
molecular
assay
dramat
chang
manag
person
hiv
hcv
quantit
number
viral
copi
achiev
naat
extrem
benefici
initi
diseas
diagnosi
also
assess
prognosi
monitor
therapi
acquir
inform
regard
resist
marker
molecular
assay
also
significantli
affect
care
immunosuppress
individu
hcv
infect
benefit
person
treatment
option
base
result
quantit
pcr
genotyp
viru
list
avail
assay
hiv
hcv
detail
tabl
global
preval
million
peopl
infect
hcv
account
major
proport
chronic
viral
hepat
case
worldwid
public
health
effort
control
hcv
primarili
involv
case
find
diagnosi
acut
chronic
infect
avail
new
treatment
modal
sustain
virolog
respons
achiev
molecular
assay
play
key
role
diagnosi
manag
hcv
fact
viru
origin
identifi
use
molecular
techniqu
flaviviru
difficult
cultur
current
diagnost
algorithm
hcv
includ
use
serolog
assay
detect
antibodi
posit
follow
naat
confirm
stage
infect
posit
naat
indic
chronic
activ
infect
hcv
neg
naat
presenc
antihcv
antibodi
indic
spontan
resolut
infect
howev
repeat
naat
advis
month
lowlevel
viremia
uncommon
chronic
hcv
addit
viral
rna
detect
serum
earli
week
exposur
use
evalu
occup
exposur
hcv
routin
use
quantit
naat
also
recommend
initi
therapi
chronic
hcv
monitor
virolog
respons
therapi
qualit
naat
detect
hcv
rna
iuml
equal
sensit
genotyp
quantit
pcr
assay
hcv
lower
limit
detect
rna
copiesml
clinic
laboratori
switch
use
quantit
assay
determin
hcv
genotyp
becom
import
determin
type
therapi
institut
howev
newer
antivir
agent
may
obviat
need
genotyp
hcv
futur
final
similar
mani
rna
virus
hcv
prone
replic
error
lead
develop
viral
quasispeci
treatment
sequenc
current
method
choic
identif
complex
viral
genotyp
circul
serum
tailor
therapi
identifi
viral
genotyp
may
resist
mutat
initi
diagnosi
hiv
infect
achiev
primarili
serolog
assay
current
fifthgener
hiv
assay
test
antibodi
antigenemia
simultan
significantli
reduc
window
period
diagnosi
hiv
infect
low
day
exposur
molecular
assay
diagnosi
hiv
primarili
use
earli
infect
especi
occup
exposur
test
infant
born
hivposit
mother
matern
antibodi
preclud
use
serolog
assay
naat
primarili
use
monitor
progress
diseas
respons
therapi
hiv
infect
hcv
genotyp
import
recogn
drugresist
mutant
aris
therapi
perhap
signific
impact
molecular
test
prevent
hospitalacquir
infect
success
nasal
methicillinresist
aureu
mrsa
screen
activ
surveil
screen
mrsa
molecular
assay
common
practic
hospit
laboratori
especi
state
mandatori
requir
mrsa
screen
report
mrsacolon
patient
reservoir
selfinfect
diseas
transmiss
molecular
assay
contribut
earli
identif
isol
carrier
elimin
carriag
reduc
potenti
transmiss
success
activ
surveil
test
demonstr
research
illinoi
use
rtpcr
test
nasal
mrsa
surveil
patient
studi
period
baselin
intens
care
unitonli
test
univers
admiss
test
clinic
cultur
perform
detect
mrsa
infect
primari
outcom
chang
clinic
mrsa
diseas
found
signific
reduct
mrsa
clinic
diseas
intens
care
unit
test
period
diseas
reduct
univers
admiss
test
conclud
activ
surveil
test
combin
contact
isol
isol
plu
decolon
achiev
low
mrsa
health
careassoci
infect
rate
infect
per
patient
day
although
detect
mrsa
rtpcr
involv
amplif
meca
gene
use
singleplex
rtpcr
applic
method
direct
specimen
nonsteril
site
nasal
swab
straightforward
reason
first
presenc
commens
coagulaseneg
staphylococci
nose
may
also
possess
meca
gene
caus
primer
target
meca
gene
produc
falseposit
result
commerci
assay
xpert
mrsa
cepheid
geneohm
mrsa
bd
diagnost
spark
md
use
primer
direct
scc
mecorfx
junction
region
aureu
chromosom
meca
gene
incorpor
ensur
detect
mrsa
coagulaseneg
staphylococci
target
second
issu
regard
detect
mrsa
nonsteril
site
involv
primer
target
scc
mecorfx
junction
meca
gene
incorpor
aureu
chromosom
disadvantag
methodolog
falseposit
result
mrsa
occur
aureu
isol
function
meca
gene
empti
cassett
variant
detect
primer
regardless
limit
mrsa
nasal
screen
pcr
wide
use
significantli
reduc
turnaround
time
hour
hour
mrsa
screen
pcr
neonat
intens
care
unit
low
posit
predict
valu
variabl
reproduc
compar
cultur
especi
cultureneg
patient
reason
institut
opt
use
cultur
screen
neonat
intens
care
unit
clostridium
difficil
associ
diarrhea
c
difficil
major
caus
morbid
prolong
hospit
stay
signific
econom
burden
health
care
system
although
naat
assay
highli
sensit
specif
diagnosi
c
difficil
diseas
pcr
challeng
asymptomat
carriag
c
difficil
uncommon
hospit
patient
care
interpret
result
requir
differenti
infect
colon
fact
laboratori
specimen
accept
polici
includ
reject
form
stool
repeat
specimen
collect
within
day
similar
reason
recommend
test
interpret
caution
infant
caus
diarrhea
rule
children
year
age
sever
fdaapprov
commerci
assay
avail
rtpcr
target
gene
encod
toxin
b
tcdb
either
use
taqman
probe
progastro
cd
test
prodess
waukesha
wi
molecular
beacon
geneohm
cdiff
assay
bd
diagnost
san
diego
ca
xpert
c
difficil
test
cepheid
differ
multiplex
assay
amplifi
differ
gene
specif
toxigen
strain
c
difficil
one
encod
toxin
b
tcdb
one
regul
toxin
product
tcdc
analyt
sensit
xpert
c
difficil
assay
cepheid
rang
coloni
form
unitsswab
depend
strain
c
difficil
http
regardless
assay
format
use
posit
pcr
assay
indic
patient
posit
toxigen
strain
c
difficil
asymptomat
patient
pcr
assay
c
difficil
use
even
test
cure
problem
compound
fact
multiplex
gastrointestin
gi
panel
biofir
filmarray
salt
lake
citi
ut
includ
c
difficil
one
target
caus
report
dilemma
asymptomat
carriag
c
difficil
regardless
clinic
suspicion
similar
reason
test
c
difficil
recommend
children
year
age
clinic
ill
rare
report
month
age
possibl
neonatesinf
may
lack
cellular
machineri
bind
process
toxin
c
difficil
infect
preventionist
awar
possibl
falseposit
c
difficil
result
work
laboratori
clinician
correctli
interpret
result
concern
mechan
vancomycin
resist
enterococci
due
presenc
vana
vanb
gene
locat
mobil
element
oppos
chromosom
mediat
vancomycin
resist
gene
eg
vanc
risk
factor
acquir
nosocomi
vancomycinresist
enterococci
vre
includ
proxim
anoth
patient
vre
prior
antibiot
therapi
extend
hospit
stay
detect
isol
patient
colon
vre
reduc
transmiss
shown
decreas
vre
bacteremia
rate
infect
prevent
strategi
often
includ
screen
patient
vre
carriag
isol
posit
patient
limit
spread
resist
organ
avail
technolog
screen
vre
follow
xpert
vana
cepheid
rtpcr
use
taqman
probe
detect
vana
gene
accept
specimen
type
rectal
swab
limit
detect
coloni
form
unit
simul
rectal
swab
xpert
vana
assay
turnaround
time
hour
http
geneohm
vanr
bd
diagnost
pcr
assay
use
molecular
beacon
detect
vana
vanb
assay
run
smartcycl
cepheid
amplifi
detect
interpret
signal
accept
specimen
type
perian
rectal
swab
analyt
sensit
approxim
coloni
form
unitsswab
turnaround
time
hour
determin
vre
colon
statu
rttpcr
method
prompt
earli
infect
control
measur
isol
therebi
prevent
nosocomi
transmiss
sensit
specif
geneohm
vanr
report
respect
compar
cultur
screen
carbapenemresist
enterobacteriacea
cre
carriag
among
inpati
issu
heighten
concern
recent
outbreak
hospit
infect
associ
spread
cre
contamin
devic
garner
attent
media
prompt
fda
issu
guidanc
strategi
limit
occurr
event
http
wwwcdcgovhaioutbreak
cdcstatementlacrehtml
carbar
assay
cepheid
rtpcr
capabl
target
known
carbapenem
resist
plasmid
recent
receiv
fda
approv
analyz
bacteri
coloni
rectal
swab
http
wwwaccessdatafdagovcdrhdoc
one
caveat
current
molecular
assay
cre
detect
known
sequenc
detect
therefor
respect
cre
larg
number
plasmid
describ
prudent
know
institut
preval
plasmid
conduct
period
review
local
antibiogram
tradit
differenti
diagnosi
mening
diarrhea
sepsi
respiratori
infect
includ
pneumonia
depend
clinic
suspicion
probabl
etiolog
agent
follow
seri
laboratori
test
detect
pathogen
major
paradigm
shift
stepwis
approach
begin
replac
complex
multiplex
panel
capabl
detect
numer
target
singl
specimen
therefor
gi
mening
respiratori
pathogen
panel
develop
deploy
health
care
set
rapid
sensit
highli
comprehens
panel
target
select
relev
pathogen
particular
specimen
type
exampl
filmarray
meningitisenceph
panel
evalu
cerebrospin
fluid
specimen
differ
pathogen
includ
bacteria
neisseria
meningitidi
virus
herp
simplex
viru
hsv
fungi
cryptococcu
neoforman
cryptococcu
gattii
littl
hour
although
assay
expens
advantag
simplifi
specimen
collect
reduc
delay
diagnosi
associ
recollect
retest
specimen
multipl
differ
pathogen
furthermor
use
panelbas
test
often
lead
specif
antimicrobi
therapi
rather
broadspectrum
therapeut
approach
addit
econom
impact
shorter
hospit
stay
institut
appropri
infect
prevent
measur
may
render
approach
even
appeal
health
care
facil
option
implement
strategi
limit
expand
test
base
patient
popul
turnaround
time
infect
prevent
protocol
sepsi
one
lead
caus
death
despit
advanc
critic
care
earli
diagnosi
therapi
critic
need
balanc
antimicrobi
stewardship
effort
nonspecif
sign
symptom
make
prompt
laboratori
diagnosi
import
although
blood
cultur
mainstay
diagnosi
rapid
techniqu
often
sought
depend
advent
molecular
panel
use
posit
blood
cultur
specimen
identif
pathogen
possibl
hour
panel
actual
detect
presenc
drug
resist
gene
meca
vana
gene
identifi
pathogen
mrsa
enterococcu
spp
two
panel
frequent
use
vergien
blood
cultur
test
nanospher
filmarray
blood
cultur
identif
panel
verigen
use
microarray
technolog
identifi
bacteria
resist
mechan
hour
organ
dna
hybrid
microarray
detect
signal
amplif
filmarray
panel
use
nest
multiplex
pcr
melt
curv
analysi
identifi
bacteria
yeast
resist
mechan
approxim
hour
conjunct
antimicrobi
stewardship
assay
help
direct
appropri
treatment
sensit
specif
detect
still
limit
target
includ
panel
addit
polymicrobi
cultur
sensit
may
equal
organ
affect
overal
perform
although
assay
shorten
time
identif
pathogen
still
depend
initi
posit
blood
cultur
septifast
system
roch
diagnost
indianapoli
probebas
rtpcr
platform
target
ribosom
sequenc
detect
commonli
isol
organ
directli
blood
fda
clear
use
clinic
europ
success
recent
fdaclear
panel
biosystem
lexington
autom
system
complet
extract
amplif
detect
candida
spp
directli
blood
detect
system
uniqu
amplifi
product
detect
ampliconinduc
agglomer
supermagnet
particl
magnet
reson
measur
use
instrument
recent
clinic
trial
system
shown
overal
sensit
specif
respect
blood
cultur
specimen
spike
known
concentr
candida
spp
multitud
exist
viral
pathogen
caus
respiratori
diseas
steadi
emerg
new
virus
greatli
challeng
diagnost
laboratori
multiplex
pcr
assay
respiratori
virus
made
tremend
impact
diagnost
laboratori
infect
control
practic
increas
sensit
faster
turnaround
time
assay
significantli
increas
laboratori
capac
detect
respiratori
virus
also
ensur
earli
initi
appropri
therapi
reduct
use
antibiot
time
implement
isol
precaut
infect
preventionist
multiplex
pcr
assay
also
complement
syndrom
surveil
public
health
author
identif
respiratori
virus
circul
commun
sever
commerci
avail
assay
variabl
technolog
complex
handson
time
gener
compar
perform
characterist
tabl
assay
verigen
rv
flex
panel
nanospher
provid
option
phase
releas
result
therefor
result
common
virus
influenza
rsv
releas
first
less
common
agent
suppress
physician
request
result
sever
studi
shown
use
rapid
respiratori
pathogen
panel
rpp
test
allow
patient
viral
bacteri
respiratori
ill
quickli
diagnos
equat
shorter
length
hospit
stay
earlier
initi
antivir
therapi
appropri
eg
influenza
studi
also
show
use
rpp
significantli
affect
isol
infect
prevent
antimicrobi
stewardship
effort
landscap
molecular
test
chang
develop
small
rapid
analyz
easi
use
requir
littl
handson
time
featur
facilit
placement
instrument
outsid
laboratori
clinic
emerg
depart
pointofcar
test
especi
use
situat
result
lead
rapid
initi
cessat
therapi
possibl
patient
might
lost
followup
diagnosi
sti
patient
risk
factor
associ
highrisk
behavior
case
respiratori
viru
test
pointofcar
test
result
aid
significantli
clinic
decisionmak
coba
liat
roch
small
new
pointofcar
rtpcr
instrument
clinic
laboratori
improv
amend
waiv
influenza
ab
streptococcu
test
test
take
minut
sampl
result
http
wwwcobasliatcom
one
studi
found
compar
simplexa
flu
ab
rsv
direct
focu
diagnost
cypress
ca
coba
liat
roch
sensit
influenza
sensit
influenza
b
specif
target
aler
aler
inc
waltham
small
rapid
isotherm
nucleic
acid
amplif
system
perform
test
influenza
ab
streptococcu
test
sampl
answer
clia
waiv
sensit
aler
influenza
ab
respect
compar
combin
filmarray
respiratori
panel
prodess
proflu
rtpcr
holog
genprob
inc
specif
aler
influenza
ab
target
least
gi
panel
receiv
fda
clearanc
other
pipelin
use
multiplex
panel
diagnosi
justifi
nonspecif
symptom
rel
insensit
convent
techniqu
microscopi
detect
ova
parasit
assay
use
rtpcr
filmarray
gi
panel
pcr
follow
beadbas
hybrid
xtag
luminex
corp
austin
tx
achiev
rel
high
sensit
specif
howev
drawback
pick
lowlevel
carriag
enteropathogen
giardia
escherichia
coli
campylobact
mani
virus
clinic
signific
especi
develop
countri
costeffect
gi
panel
also
debat
fact
molecular
assay
leav
laboratori
without
option
perform
suscept
test
epidemiolog
treatment
purpos
mening
panel
process
adopt
laboratori
although
data
limit
diagnost
perform
seem
promis
platform
consid
benefici
rapid
diagnosi
mening
promis
technolog
potenti
chang
practic
infect
control
forese
futur
ng
technolog
appli
wholegenom
sequenc
wg
tabl
current
avail
commerci
panel
diagnosi
respiratori
viral
infect
assay
name
alreadi
produc
signific
advanc
epidemiolog
phylogenet
virul
determin
evolut
antimicrobi
resist
microbi
pathogen
sever
technolog
current
use
mostli
involv
dna
extract
prepar
librari
follow
sequenc
synthesi
gener
short
read
except
technolog
pacbio
rsii
pacif
bioscienc
menlo
park
ca
oxford
nanopor
oxford
nanopor
technolog
oxford
uk
gener
long
read
short
dna
fragment
read
map
refer
genom
use
softwar
technolog
use
well
describ
sever
recent
review
ng
technolog
becom
amen
use
clinic
laboratori
associ
cost
decreas
advanc
bioinformat
pipelin
like
concomit
increas
use
wg
predict
antimicrobi
resist
track
epidemiolog
spread
microb
exampl
use
sequenc
data
gener
identif
suscept
achiev
limit
time
elucid
recent
public
bradley
et
al
use
oxford
nanopor
technolog
author
abl
predict
suscept
aureu
tuberculosi
minut
laptop
comput
softwar
use
mykrobepredictorcom
provid
sensit
specif
aureu
respect
tuberculosi
noth
satisfi
field
epidemiolog
prevent
spread
microb
outbreak
studi
evolut
pathogen
time
scienc
phylogeni
appli
track
outbreak
come
long
way
sinc
snow
establish
associ
broad
street
pump
spread
cholera
outbreak
london
technolog
wg
appli
studi
spread
drugresist
organ
singl
facil
also
largescal
epidemiolog
studi
monitor
evolut
spread
pathogen
time
barrier
widespread
use
ng
infect
control
includ
concern
regard
data
qualiti
effici
use
bioinformat
clinic
laboratori
beyond
assur
qualiti
control
standard
need
infrastructur
evid
success
use
wg
infect
control
needless
say
technolog
great
potenti
may
immens
util
futur
world
microbiolog
chang
sinc
van
leeuwenhoek
first
observ
realm
microb
understand
intric
natur
microbiom
complex
pathogenesi
infect
significantli
built
koch
postul
first
allow
us
understand
infecti
diseas
identifi
precis
character
emerg
pathogen
trace
sourc
outbreak
matter
day
exemplifi
german
outbreak
enterohemorrhag
e
coli
diseas
previous
discuss
numer
assay
choos
choic
would
depend
rel
perform
assay
cost
complex
infrastructur
laboratori
patient
popul
serv
embark
new
path
person
medicin
enhanc
util
laboratori
respons
laboratorian
physician
infect
preventionist
increas
advent
newer
technolog
onu
fall
us
determin
clinic
util
costeffect
techniqu
educ
stakehold
effici
use
interpret
result
better
patient
care
furthermor
need
remain
forefront
technolog
understand
benefit
shortcom
continu
improv
diagnosi
control
infecti
diseas
